AEM vs CRH

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

CRH exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. While the current price of $118.00 trades at a significant premium to its Graham Number ($66.71), it remains well below its growth-based intrinsic value of $162.54. The company is outperforming its sector in valuation (P/E 21.42 vs Sector Avg 37.99) and profitability, supported by an impressive 48.4% YoY earnings growth. Despite a bearish technical trend, the strong analyst consensus and healthy balance sheet suggest a compelling long-term value proposition.